Enterprise Value

52.05M

Cash

345.7M

Avg Qtr Burn

-44.25M

Short % of Float

5.62%

Insider Ownership

5.66%

Institutional Own.

78.93%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tarcocimab (KSI-301) (anti-VEGF) Details
Non-proliferative diabetic retinopathy

Phase 3

Update

KSI-501 (anti-VEGF & IL-6) Details
Diabetic macular edema, Eye disease

Phase 1

Update

Failed

Discontinued

Tarcocimab (KSI-301) Details
Retinal vein occlusion

Failed

Discontinued

Tarcocimab (KSI-301) Details
Wet age-related macular degeneration

Failed

Discontinued